Astellas's First-In-Class CLDN18 Antibody Meets Phase III Gastric Endpoints
Competitive Advantage Vs Opdivo?
Novel candidate acquired from Ganymed in 2016 moves closer to first approval filing anywhere for a CLDN18-targeting antibody, and as a potential competitor for Opdivo in HER2-negative gastric cancer, following positive top-line Phase III results in the first-line combo setting. Results from GLOW trial in combination with CAPOX also awaited.
